Get the Stockscreener App
0.0724
8.52%
-0.0062
Spruce Biosciences Inc stock is traded at $0.0724, with a volume of 188.27K.
It is down -8.52% in the last 24 hours and down -74.38% over the past month.
See More
Previous Close:
$0.0786
Open:
$0.069925
24h Volume:
188.27K
Relative Volume:
573.16
Market Cap:
$N/A
Revenue:
$7.10M
Net Income/Loss:
$-39.43M
P/E Ratio:
-0.077
EPS:
-0.94
Net Cash Flow:
$-46.50M
1W Performance:
-8.52%
1M Performance:
-74.38%
6M Performance:
-86.69%
1Y Performance:
-90.34%
1-Day Range:
$0.0695
$0.0724
1-Week Range:
$0.0695
$0.0724
52-Week Range:
$0.0695
$0.0724
Spruce Biosciences Inc Stock (SPRB) Company Profile
Compare SPRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
0.0724 | 0 | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market - MSN
Spruce Biosciences (SPRB) Secures Nasdaq Approval for Relisting - GuruFocus
Spruce Biosciences Announces Conditional Nasdaq Approval to Resu - GuruFocus
# Spruce Biosciences to resume Nasdaq trading pending stock split approval By Investing.com - Investing.com South Africa
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market - BioSpace
Spruce Biosciences regains Nasdaq compliance path By Investing.com - Investing.com South Africa
Spruce Biosciences regains Nasdaq compliance path - Investing.com
# Spruce Biosciences to resume Nasdaq trading pending stock split approval - Investing.com
Spruce Biosciences’ Compliance Plan Accepted by Nasdaq - TipRanks
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market | SPRB Stock News - GuruFocus
Neurocrine Loses Suit Challenging Hormone Treatment Patent - Law360
Judge Tosses Neurocrine’s Suit Over Spruce Hormone-Drug Patent - Bloomberg Law News
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
Congenital Adrenal Hyperplasia Market Growth Projections - openPR.com
Berkshire Near All-time Highs: Could This Be Buffett's Final Defining Act? - The Globe and Mail
Time to Buy These 3 Cheap Stocks? - The Globe and Mail
If I Could Only Buy and Hold a Single Stock, This Would Be It - The Globe and Mail
Is Chipotle Mexican Grill Stock Underperforming the S&P 500? - The Globe and Mail
Is Palo Alto Networks Stock Outperforming the S&P 500? - The Globe and Mail
Is Amphenol Stock Outperforming the Dow? - The Globe and Mail
What Nvidia, AMD, and CoreWeave Stock Investors Should Know About the Recent AI Training Benchmark - The Globe and Mail
Spruce Biosciences Enters Purchase Agreement with Board Chair - TipRanks
Top 100 Stocks to Buy: Is Amer Sports Stock Ready to Head Downhill? - The Globe and Mail
FY2025 EPS Estimates for OTCMKTS:GTBIF Reduced by Analyst - Defense World
Axalta Coating Systems (NYSE:AXTA) Price Target Raised to $40.00 - Defense World
FY2025 EPS Estimates for InnovAge Decreased by William Blair - Defense World
Guggenheim Forecasts Strong Price Appreciation for Wingstop (NASDAQ:WING) Stock - Defense World
What is Seaport Res Ptn’s Forecast for FWONA Q3 Earnings? - Defense World
Spruce Biosciences (SPRB) Expected to Announce Quarterly Earnings on Monday - Defense World
Leerink Partnrs Issues Positive Outlook for SPRB Earnings - Defense World
Spruce Biosciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Spruce Biosciences (SPRB) - ACCESS Newswire
'It's a mess out there': More biotech layoffs mean stiff competition for jobs at emerging companies - The Business Journals
Renaissance Technologies LLC Reduces Stock Holdings in Spruce Biosciences, Inc. (NASDAQ:SPRB) - Defense World
Spruce Biosciences Reports Q1 2025 Results and Updates - TipRanks
Spruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacks By Investing.com - Investing.com Nigeria
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - Bluefield Daily Telegraph
Spruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacks - Investing.com
Geron (GERN) to Post Earnings on Wednesday - Defense World
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
Q1 EPS Forecast for Spruce Biosciences Reduced by Analyst - Defense World
Spruce to move tralesinidase alfa into Phase 3 clinical study - Sanfilippo Syndrome News
The Psychology of Allarity Therapeutics Inc Inc. (ALLR) Price Performance: Understanding Market Sentiment - investchronicle.com
Oppenheimer gives a Perform recommendation for Spruce Biosciences Inc (SPRB) - knoxdaily.com
Closing Figures: Spruce Biosciences Inc (SPRB)’s Negative Finish at 0.08, Down -39.45 - DWinneX
Spruce Biosciences Inc [SPRB] Stock trading around $0.08 per share: What’s Next? - dbtnews.com
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga
Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe - Endpoints News
SPRB stock touches 52-week low at $0.09 amid market challenges - Investing.com
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.50%
Cap:
|
Volume (24h):